Press Releases May 12, 2026 04:05 PM

Robinhood Markets, Inc. to Present at the J.P. Morgan Global Technology, Media and Communications Conference on May 19, 2026

Robinhood Markets to Present at J.P. Morgan Global Technology, Media and Communications Conference on May 19, 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
HOOD

Robinhood Markets, Inc. announced that its Chief Brokerage Officer will present at the J.P. Morgan Global Technology, Media and Communications Conference on May 19, 2026. The presentation will be webcast live and available for replay, providing insights into the company's business and strategy. This participation offers transparency and engagement with investors in the technology and financial services sectors.

Robinhood Markets, Inc. to Present at the J.P. Morgan Global Technology, Media and Communications Conference on May 19, 2026
HOOD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Robinhood Markets will present at a prominent industry conference, signaling openness to investor engagement.
  • The event will be accessible via a webcast, broadening reach to investors and analysts interested in fintech and brokerage services.
  • Robinhood highlights its diverse offerings including retail brokerage, crypto, advisory, digital banking, and private markets access, underscoring its multi-faceted financial services platform.

MENLO PARK, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today announced that it will be participating in the upcoming J.P. Morgan Global Technology, Media and Communications Conference on May 19, 2026.

Robinhood’s Chief Brokerage Officer Steve Quirk is scheduled to present on Tuesday, May 19, 2026, at 11:25 AM ET / 8:25 AM PT. Interested parties may access a live audio webcast of the presentation by visiting investors.robinhood.com. Following the presentation, a recording will be available for replay for at least 90 days on the same website.

About Robinhood

Robinhood Markets, Inc. (NASDAQ: HOOD) is a global leader in financial services offering retail brokerage, crypto, advisory, digital banking services, and private markets access to a new generation of investors. Additional information about Robinhood can be found at robinhood.com.

Robinhood uses the “Overview” tab of its Investor Relations website (accessible at investors.robinhood.com/overview) and its Newsroom (accessible at newsroom.aboutrobinhood.com), as means of disclosing information to the public in a broad, non-exclusionary manner for purposes of the SEC Regulation Fair Disclosure (Reg. FD). Investors should routinely monitor those web pages, in addition to Robinhood’s press releases, SEC filings, and public conference calls and webcasts, as information posted on them could be deemed to be material information.

“Robinhood” and the Robinhood feather logo are registered trademarks of Robinhood Markets, Inc. All other names are trademarks and/or registered trademarks of their respective owners.

Contacts

Investor Relations: ir@robinhood.com

Press: press@robinhood.com


Risks

  • The presentation may reveal strategic directions that could be met with uncertainty or investor skepticism affecting stock performance.
  • Market conditions in the financial services and technology sectors remain volatile, potentially impacting investor sentiment following the presentation.
  • Regulatory developments affecting fintech and cryptocurrency services could pose ongoing risks to Robinhood's business model and market valuation.

More from Press Releases

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress Jun 14, 2026 Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026